Clinical Determinants Influencing First-line Immune Checkpoint Inhibitor Selection for Unresectable Hepatocellular Carcinoma in Japan
Anticancer Research · 2026
DOI: 10.21873/anticanres.18402 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Anticancer Research, 2026. Verfasst von Kensuke Yoshida und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Drug Safety and Risk Management, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan; yoshida@toyaku.ac.jp. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Immune Checkpoint Inhibitors, Antineoplastic Combined Chemotherapy Protocols.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Drug Safety and Risk Management, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan; yoshida@toyaku.ac.jp.
- Laboratory of Drug Safety and Risk Management, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.
- Department of Medical Oncology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
- Department of Medical Oncology, Niigata City General Hospital, Niigata, Japan.
- Department of Pharmacoepidemiology, Showa Medical University Graduate School of Pharmacy, Tokyo, Japan.
Zitieren
APA
Yoshida, K., Kubo, I., Kiyomi, A., Homma, Y., Zhou, Q., Imai, S., & Sugiura, M. (2026). Clinical Determinants Influencing First-line Immune Checkpoint Inhibitor Selection for Unresectable Hepatocellular Carcinoma in Japan. Anticancer Research. https://doi.org/10.21873/anticanres.18402
Vancouver
Yoshida K, Kubo I, Kiyomi A, Homma Y, Zhou Q, Imai S, et al. Clinical Determinants Influencing First-line Immune Checkpoint Inhibitor Selection for Unresectable Hepatocellular Carcinoma in Japan. Anticancer Research. 2026. doi:10.21873/anticanres.18402
BibTeX
@article{Yoshida2026,
author = {Yoshida, Kensuke and Kubo, Ibuki and Kiyomi, Anna and Homma, Yujiro and Zhou, Qiliang and Imai, Shinobu and Sugiura, Munetoshi},
title = {Clinical Determinants Influencing First-line Immune Checkpoint Inhibitor Selection for Unresectable Hepatocellular Carcinoma in Japan},
journal = {Anticancer Research},
year = {2026},
doi = {10.21873/anticanres.18402}
}
EUVIMED